Several clinical studies are currently in progress to assess the effects of co-administering adoptive NK cell CYNK-101, an NK cell line optimized for IgG binding, with anti-CD38 mAb Daratumumab (43) or anti-HER2 Trastuzumab and Pembrolizumab (NCT05207722) for cancer treatment. Here, ERBB2 is linked to cancer.